111 related articles for article (PubMed ID: 29699792)
1. Long-term immunogenicity of a quadrivalent human papillomavirus vaccine in systemic lupus erythematosus.
Mok CC; Ho LY; To CH
Vaccine; 2018 May; 36(23):3301-3307. PubMed ID: 29699792
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study.
Mok CC; Ho LY; Fong LS; To CH
Ann Rheum Dis; 2013 May; 72(5):659-64. PubMed ID: 22589375
[TBL] [Abstract][Full Text] [Related]
3. The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus.
Dhar JP; Essenmacher L; Dhar R; Magee A; Ager J; Sokol RJ
Vaccine; 2017 May; 35(20):2642-2646. PubMed ID: 28404357
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and persistence of immunity of a quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children.
MacIntyre CR; Shaw P; Mackie FE; Boros C; Marshall H; Barnes M; Seale H; Kennedy SE; Moa A; Hayen A; Chughtai AA; O'Loughlin EV; Stormon M
Vaccine; 2016 Aug; 34(36):4343-50. PubMed ID: 27406936
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with childhood systemic lupus erythematosus: a real-world interventional multi-centre study.
Rotstein Grein IH; Pinto NF; Lobo A; Groot N; Sztajnbok F; da Silva CAA; Paim Marques LB; Appenzeller S; Islabão AG; Magalhães CS; de Almeida RG; Bica B; Fraga M; da Fraga ACM; Dos Santos MC; Robazzi T; Terreri MTR; Bandeira M; Pasmans H; Schepp R; van der Klis F; de Roock S; Wulffraat N; Pileggi G
Lupus; 2020 Jul; 29(8):934-942. PubMed ID: 32501172
[TBL] [Abstract][Full Text] [Related]
6. Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up.
Huang T; Liu Y; Li Y; Liao Y; Shou Q; Zheng M; Liao X; Li R
Vaccine; 2018 Mar; 36(11):1368-1374. PubMed ID: 29428178
[TBL] [Abstract][Full Text] [Related]
7. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
[TBL] [Abstract][Full Text] [Related]
8. Long term follow up of persistence of immunity following quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children.
MacIntyre CR; Shaw PJ; Mackie FE; Boros C; Marshall H; Seale H; Kennedy SE; Moa A; Chughtai AA; Trent M; O'Loughlin EV; Stormon M
Vaccine; 2019 Sep; 37(37):5630-5636. PubMed ID: 31402238
[TBL] [Abstract][Full Text] [Related]
9. The effect of history of abnormal pap smear or preceding HPV infection on the humoral immune response to Quadrivalent Human Papilloma virus (qHPV) vaccine in women with systemic lupus erythematosus.
Dhar JP; Essenmacher L; Dhar R; Magee A; Ager J; Sokol RJ
Hum Vaccin Immunother; 2018; 14(9):2318-2322. PubMed ID: 29708835
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years.
Soybilgic A; Onel KB; Utset T; Alexander K; Wagner-Weiner L
Pediatr Rheumatol Online J; 2013; 11():29. PubMed ID: 23924237
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine.
Nygård M; Saah A; Munk C; Tryggvadottir L; Enerly E; Hortlund M; Sigurdardottir LG; Vuocolo S; Kjaer SK; Dillner J
Clin Vaccine Immunol; 2015 Aug; 22(8):943-8. PubMed ID: 26084514
[TBL] [Abstract][Full Text] [Related]
12. Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status.
Mugo NR; Eckert L; Magaret AS; Cheng A; Mwaniki L; Ngure K; Celum C; Baeten JM; Galloway DA; Wamalwa D; Wald A
Vaccine; 2018 Nov; 36(46):7025-7032. PubMed ID: 30297124
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of quadrivalent human papillomavirus types 6/11/16/18 recombinant vaccine in chronic kidney disease stage IV, V and VD.
Praditpornsilpa K; Kingwatanakul P; Deekajorndej T; Rianthavorn P; Susantitaphong P; Katavetin P; Tiranathanakul K; Srisawat N; Tungsanga K; Eiam-Ong S; Townamchai N
Nephrol Dial Transplant; 2017 Jan; 32(1):132-136. PubMed ID: 26932687
[TBL] [Abstract][Full Text] [Related]
14. Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection.
Zurek Munk-Madsen M; Toft L; Kube T; Richter R; Ostergaard L; Søgaard OS; Tolstrup M; Kaufmann AM
Hum Vaccin Immunother; 2018 Apr; 14(4):909-916. PubMed ID: 29172992
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.
Mugo N; Ansah NA; Marino D; Saah A; Garner EI
Hum Vaccin Immunother; 2015; 11(6):1323-30. PubMed ID: 25912475
[TBL] [Abstract][Full Text] [Related]
16. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.
Einstein MH; Takacs P; Chatterjee A; Sperling RS; Chakhtoura N; Blatter MM; Lalezari J; David MP; Lin L; Struyf F; Dubin G;
Hum Vaccin Immunother; 2014; 10(12):3435-45. PubMed ID: 25483701
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule.
Gilca V; Sauvageau C; Boulianne N; De Serres G; Couillard M; Krajden M; Ouakki M; Murphy D; Trevisan A; Dionne M
Hum Vaccin Immunother; 2014; 10(8):2438-45. PubMed ID: 25424952
[TBL] [Abstract][Full Text] [Related]
18. Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine.
Levin MJ; Huang S; Moscicki AB; Song LY; Read JS; Meyer WA; Saah AJ; Richardson K; Weinberg A;
Vaccine; 2017 Mar; 35(13):1712-1720. PubMed ID: 28238631
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of quadrivalent human papillomavirus vaccine among Alaska Native children aged 9-14 years at 5 years after vaccination.
Davis BM; Blake I; Panicker G; Meites E; Thompson G; Geis J; Bruden D; Fischer M; Singleton R; Unger ER; Markowitz LE; Bruce MG
Vaccine; 2024 May; 42(14):3277-3281. PubMed ID: 38627144
[TBL] [Abstract][Full Text] [Related]
20. The effect of perceived psychological stress on the immunogenicity of the quadrivalent human papillomavirus vaccine in males.
Wu RF; Zimmerman RK; Lin CJ
Hum Vaccin Immunother; 2017 Mar; 13(3):676-679. PubMed ID: 27682819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
